Telix Pharmaceuticals Says First Patients In US Dosed With Pixclara, FDA-Approved, Amino Acid Positron Emission Tomography Drug For Glioma Imaging

Telix Pharmaceuticals has announced the first doses of its FDA-approved drug Pixclara, an amino acid positron emission tomography (PET) agent for glioma imaging, have been administered in the U.S. at facilities in Cleveland and Indianapolis. This marks the beginning of Pixclara's commercial availability in the U.S., with PharmaLogic Holdings Corp. as the distribution partner. Pixclara is designed to help differentiate recurrent or progressive glioma from treatment-related changes in patients aged one month and older.